Abstract:Belatacept, a high-affinity variant of CTLA4-Ig, is a recently approved immunosuppressive agent for the prevention of acute rejection. It functions as a potent antagonist of the CD28-B7 interactions, thereby inhibiting T cell co-stimulation and activation. Experimental data involving the transient use of CTLA4-Ig to induce allograft tolerance have shaped the current paradigm that CTLA-4Ig is ineffective at inhibiting memory T cell responses, and by extension T-dependent alloantibody responses. This resistance is explained by the acquisition of additional activation-induced costimulatory molecules by memory T cells. We noted that the efficacy of CTLA4-Ig as a continuously administered drug for controlling rejection in sensitized recipients has not been investigated. Here we report on the efficacy of CTLA4-Ig in preventing acute rejection in sensitized C57BL/6 recipients that had received BALB/c spleen cell transfusion 3-6 months previously. We set up four experimental groups. Group 1 (N=5): sensitized mice with HTX and CTLA4-Ig treated (Day -2, Day 0, Day2, then weekly (1 mg/dose) Group 2 (N=3): sensitized mice with HTX and no CTLA4-Ig, Group 3: (N=10) naive mice with HTX and CTLA4-Ig treated, Group 4 (N=10): naive mice with HTX and no CTLA4-Ig. In the untreated Groups 2 & 4, allografts were rejected within 7 days post-transplantation, whereas in Group 3 of naive mice receiving CTLA4-Ig, all the grafts survived long-term (>90 days). In Group 1 of sensitized recipients receiving CTLA4-Ig, the allografts survived for 42, 42, 49, >90, >90 days. The pre-transplant donor-specific antibody (DSA) titers in the recipients that went on to reject their graft was significantly higher compared to those that accepted their grafts. Furthermore, DSA titers increased post-transplantation in the recipients that went on to reject their allografts, whereas DSA titers decreased in those that accepted their grafts. In conclusion, these observations illustrate the efficacy of CTLA-4Ig treatment at controlling rejection in sensitized recipients, and underscore the barrier pre-transplantation DSA poses to long-term graft acceptance. This experimental model also provides a unique opportunity for testing if DSA promotes antibody-mediated rejection or alloreactive memory T cell priming and T cell-mediated rejection in CTLA4-Ig treated recipients, and for identifying therapies that promote long-term graft survival in sensitized recipients.

Tectorigenin, a Phytoalexin of Centrosema haitiense and Other Centrosema Species

Impact of Regulatory T Cells on Innate Immune Cells in a Pre-Sensitized Heart Transplant Model

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Gut Microbes Enlarged the Protective Effect of Transplanted Regulatory B Cells on Rejection of Cardiac Allografts.

Role of myeloid-derived suppressor cells in mouse pre-sensitized cardiac transplant model.

Tolerance Induced by IL-6 Deficient Donor Heart is Significantly Involved in Myeloid-Derived Suppressor Cells (Mdscs).

Alteration Of Innate Immunity By Donor Il-6 Deficiency In A Presensitized Heart Transplant Model

A High Frequency of CD8+CD28- T-suppressor Cells Contributes to Maintaining Stable Graft Function and Reducing Immunosuppressant Dosage after Liver Transplantation

Intragraft memory-like CD127hiCD4+Foxp3+ Tregs maintain transplant tolerance

Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance.

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

Antibody-Suppressor CXCR5+CD8+ T Cells Are More Potent Regulators of Humoral Alloimmunity after Kidney Transplant in Mice Compared to CD4+ Regulatory T Cells

Regulatory T Cells in Transplantation Tolerance

Reduced levels of both circulating CD4+ CD25+ CD127(low/neg) and CD4+ CD8(neg) invariant natural killer regulatory T cells in stable heart transplant recipients.

T Regulatory Cells As an Immunotherapy for Transplantation

Antigen-Dependent Suppression of Alloresponses by Foxp3-Induced Regulatory T Cells in Transplantation

T regulatory cells as an immunotherapy for transplantation.

Role of CD8+ Regulatory T Cells in Organ Transplantation

Targeted depletion of PD-1–expressing cells induces immune tolerance through peripheral clonal deletion

Advances in Transplantation Tolerance

Transplantation tolerance: don't forget about the B cells